SCOLR Notified of Patent Allowance

SCOLR Notified of Patent Allowance

REDMOND, Wash.--SCOLR Inc. received notificationof allowance from the U.S. Patent Office for its amino acid CDT drug deliveryplatform for over-the-counter (OTC) and prescription drugs. The amino acid CDTplatform is one of three SCOLR patents for modified oral dosage release systems.This is the first patent issued directly to SCOLR; the first two CDT patentswere licensed exclusively by SCOLR from Temple University in Philadelphia. Whileseveral nutraceutical products using CDT are now available, the first OTC withCDT is not expected until late 2003, with a CDT-based prescription druglaunching after 2005.

David T. Howard, president and chief executive officer of SCOLR(formerly Nutraceutix), said the patent allowance positions the company as aninnovator in drug delivery. "This new capability further strengthens ourability to generate new platforms, which can sustain our predicted futuregrowth," he said.

The company also announced the successful completion of itspivotal biotrial providing Proof of Concept for Self Correcting Oral LinearRelease drug delivery systems in human subjects. The double blind trial involved18 fed and 18 fasting patients receiving daily doses of a Class 1 drug. RezaFassihi, Ph.D., professor of biopharmaceutics and industrial pharmacy at TempleUniversity, is scheduled to present the results at the American Association ofPharmaceutical Scientists meeting in Toronto this month.

For more information, visit www.nutraceutix.comor Booth #1530-1532 at SupplySide West.